Evidence map›Paper›PMID 36546425›Full record

ArticleHaematologica2023

Retrospective analysis of a cohort of 41

Caroline Algrin, Louis Pérol, Elise Chapiro, Lucile Baseggio, Karim Maloum, Catherine Settegrana, Jean-François Lesesve, Justine Siavellis, Alain Delmer, Anne-Sophie Michallet and 15 more

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Haematologica, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. The 2022 classifications of lymphoid neoplasms : Keynote.Pathologie (Heidelberg, Germany) · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Caroline AlgrinGroupe Hospitalier Mutualiste de Grenoble, Service d'Onco-Hématologie, Grenoble. caroline.algrin@avec.fr.
Louis PérolSorbonne Université, Service d'Hématologie Clinique, Hôpital Pitié-Salpêtrière, AP-HP, Paris.
Elise ChapiroSorbonne Université, Unité de Cytogénétique Hématologique, Hôpital Pitié-Salpêtrière, APHP, Paris, France; Centre de Recherche des Cordeliers, INSERM, Drug resistance in hematological malignancies (DRIHM) Team, Sorbonne Université, Université Sorbonne Paris Cité, Université Paris Descartes, Université Paris Diderot, F-75006 Paris.
Lucile BaseggioHôpital Lyon Sud, Laboratoire d'Hématologie, Hospices Civils de Lyon, Pierre-Bénite.
Karim MaloumSorbonne Université, Service d'Hématologie Biologique, Hôpital Pitié-Salpêtrière, AP-HP, Paris.
Catherine SettegranaHôpital Ambroise Paré, Laboratoire d'Hématologie, AP-HP, Boulogne-Billancourt.
Jean-François LesesveCHRU Nancy, Service d'Hématologie Biologique, INSERM 1256 NGERE, Nancy.
Justine SiavellisHôpital Avicenne, Service d'Hématologie Clinique, AP-HP, Bobigny.
Alain DelmerCHU Reims, Service d'Hématologie Clinique, Reims.
Anne-Sophie MichalletCentre Léon Bérard, Service d'Hématologie Clinique, Lyon.
Emmanuelle FerrantHôpital Lyon Sud, Service d'Hématologie Clinique, Hospices Civils de Lyon, Pierre-Bénite.
Pierre FeugierCHU Nancy, Service d'Hématologie Clinique, Vandoeuvre-lès-Nancy.
Cécile TomowiakCHU Poitiers, Service d'Hématologie Clinique, Poitiers.
Annie BrionCHU J Minjoz, Service d'Hématologie Clinique, Besançon.
David GhezInstitut Gustave Roussy, Service d'Hématologie Clinique, Villejuif.
Luc-Matthieu ForneckerService d'Hématologie, Institut de Cancérologie Strasbourg Europe (ICANS), 17 rue Albert Calmette, Strasbourg.
Sarah IvanoffHôpital Avicenne, Service d'Hématologie Clinique, AP-HP, Bobigny.
Stéphanie StruskiIUCT Oncopole - Toulouse, Laboratoire d'hématologie/Plateau Technique Hématologie-Oncologie, Toulouse.
Laurent SuttonCHU Tours, Service d'Hématologie Clinique, Tours.
Isabelle Radford-WeissCHU Necker-Enfants Malades, Laboratoire de Cytogénétique, APHP, Paris.
Virginie EclacheHôpital Avicenne, Service d'Hématologie Biologique, AP-HP, Bobigny.
Christine LefebvreCHU Grenoble Alpes, Laboratoire de Cytogénétique des Hémopathies, Grenoble.
Véronique LeblondSorbonne Université, Service d'Hématologie Clinique, Hôpital Pitié-Salpêtrière, AP-HP, Paris.
Florence Nguyen-KhacSorbonne Université, Unité de Cytogénétique Hématologique, Hôpital Pitié-Salpêtrière, APHP, Paris, France; Centre de Recherche des Cordeliers, INSERM, Drug resistance in hematological malignancies (DRIHM) Team, Sorbonne Université, Université Sorbonne Paris Cité, Université Paris Descartes, Université Paris Diderot, F-75006 Paris.
Damien Roos-WeilSorbonne Université, Service d'Hématologie Clinique, Hôpital Pitié-Salpêtrière, AP-HP, Paris, France; Centre de Recherche des Cordeliers, INSERM, Drug resistance in hematological malignancies (DRIHM) Team, Sorbonne Université, Université Sorbonne Paris Cité, Université Paris Descartes, Université Paris Diderot, F-75006 Paris. damien.roosweil@aphp.fr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Leukemia, Lymphocytic, Chronic, B-CellLeukemia, Prolymphocytic, B-CellHumansRetrospective Studies

Identifiers

PMID36546425
PMCPMC10230425

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.